

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: OLSON et al.
Appl. No.: New Group: Unknown
Filed: July 16, 2003 Examiner: Unknown
For: ADH7 NUCLEOTIDES

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Date: July 16, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).

09/720,200

U.S. Filing Date(s)

December 22, 2000

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 25-0120.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

By Philip A. DuBois
Philip A. DuBois, #50,696

PD/psf

745 South 23rd Street
Arlington, Virginia 22202
(703) 521-2297

Enclosures: ☒ PTO-1449
☐ References
☐ Foreign Search Report
☐ Other:

(Rev. 04/19/2000)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small> (37 CFR 1.98(b))	ATTY. DOCKET NO. 1522-1001-1	SERIAL NO.
	APPLICANT Lars OLSON et al.	
	FILING DATE July 16, 2003	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,514,825	05/96	VULIGONDA et al.			
	AB						
	AC						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AD	GB 2 292 522	02/96	United Kingdom			N/A

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AE	H. YOKOYAMA et al., <i>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS</i> , Vol. 216, No. 1, 1995, "Upstream Structure of Human ADH7 Gene and the Organ Distribution of its Expression" page 216-222
AF	M. ZGOMBIC-KNIGHT, <i>THE JOURNAL OF BIOLOGICAL CHEMISTRY</i> , Vol. 20, No. 9, March 1995, "Genomic Structure and expression of the ADH7 Gene Encoding Human Class IV alcohol Dehydrogenase, the Form Most Efficient for Retinol Metabolism in Vitro", pages 4305-4311
AG	S. TA et al, <i>PROC. NATL. ACAD. SCI.</i> , Vol. 94, No. 26, December 1997, "Regulation of Dopaminergic Pathways by Retinoids: Activation of the D2 Receptor Promoter By Members of the Retinoic Acid receptor-Retinoic X Receptor Family", page 1439-14354
AH	R.H. ZETTERSTROM et al., <i>MOLECULAR ENDOCRINOLOGY</i> , Vol. 10, No. 12, 1996, Retinoic X Receptor Heterodimerization and Developmental Expression Distinguish the Orphan Nuclear Receptors NGFI-B, Nurrl, and Norl", page 1656-166
AI	P. McCaffery et al., <i>PROC. NATL. ACAD. SCI.</i> , Vol. 91, August 1994, "High Levels of a Retinoic Acid-generating Dehydrogenase in the Meso-telencephalic Dopamine System", page 7772-7776

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1522-1001-1

SERIAL NO.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use several sheets if necessary)

37 CFR 1.98(b)

APPLICANT
Lars OLSON et al.

FILING DATED
July 16, 2003

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AT	Buervenich et al., Mov. Disord 15:813-818, September, 2000
AU	Tan et al., Neuroscience Letters 305:70-72, 2001
AV	Zgombic-Knight et al., J. Biol. Chem. 270:4305-4311, 1995, EMBL accession numbers U16286-U16293, 1995
AX	Yokoyama et al., GenEMBL accession number L39009, March 7, 1996
AY	Sage-Ono, GenEMBL accession number D85101, May 2, 1998

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

37 CFR 1.98(b)

ATTY. DOCKET NO.
1522-1001-1

SERIAL NO.

APPLICANT
Lars OLSON et al.

FILING DATE
July 16, 2003

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AT	Glass et al., GenEMBL accession number U30500, September 1, 1995
AU	Carson et al., GenEMBL AA080645, October 28, 1997
AV	Mathews et al., GenEMBL accession number U17249, September 27, 1995
AX	NCI-CGAP, GenEMBL accession number AA906249, May 19, 1998
AY	King et al., GenEMBL accession number L41145, April 1, 1995

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1522-1001-1

SERIAL NO.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use several sheets if necessary)

37 CFR 1.98(b)

APPLICANT
Lars OLSON et al.

FILING DATED
July 16, 2003

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AT	Bork, Genome Research, 10:348-400, 2000.
AU	Broun et al., Science 282:1315-1317, 1998.
AV	Van de Loo et al., Proc. Natl. Acad. Sci. 92:6743-6747, 1995
AX	
AY	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.